Home › Stem Cell Cures

Stem Cell Cures

News Story
12/6/2012
Posted by Mark Reback
Agency should split operations from policy, add more oversight committee members without conflicts California's $3 billion stem cell agency should reduce its built-in conflicts of interests or risk losing effectiveness, according to a report released today from the prestigious National Academy of Sciences. The academy's report said the...
News Story
12/6/2012
Posted by Mark Reback
The California Institute of Regenerative Medicine received a mixture of praise and hard-to-enact recommendations from an august scientific body today. Last summer, CIRM asked the Institute of Medicine to gather a group of experts to assess the stem-cell institute’s performance, which has distributed more than $1.3 billion to California...
News Story
12/6/2012
Posted by Mark Reback
A review of California's stem cell research funding agency proposed changes to the agency's governing structure and commercial goals while praising its results so far. The 124-page report from the Institute of Medicine recycles many conflict of interest and intellectual property concerns that have dogged the San Francisco-based California...
News Story
4/13/2012
Posted by Mark Reback
A committee convened by the US Institute of Medicine (IOM) heard testimony on 10 April about shortcomings of the San Francisco-based California Institute for Regenerative Medicine (CIRM). And although members of the IOM committee asked probing questions about CIRM’s structure and performance, looming over the review is the reality that it...
News Story
3/18/2012
Posted by Mark Reback
LOS ANGELES (AP) -- The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions. The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds...
News Story
12/9/2011
Posted by Mark Reback
Touted seven years ago as a way to develop "breakthrough cures" for an array of life-threatening ailments, California's $3 billion taxpayer-financed stem cell agency still has no treatments on the market and is at a critical juncture that could determine how much longer it stays in operation. The agency will dole out the last of...
News Story
9/26/2011
Posted by Mark Reback
  Allocation of state stem cell grants in San Diego and Riverside counties Was it worth it? Nearly seven years ago, California voters approved the state's landmark stem cell research program. Taxpayers funded $6 billion in state bonds for the program under Proposition 71. After interest, that left $3 billion...
News Story
7/5/2011
Posted by Mark Reback
As other agencies scale back, the top two officials at the California Institute for Regenerative Medicine have combined salaries of nearly $1 million a year. Reporting from Sacramento -- California's stem cell research agency says it needs billions more taxpayer dollars to deliver on promised cures to major diseases. Yet at a time when...
News Story
6/23/2011
Posted by Mark Reback
LOS ANGELES — An investment banker with an interest in biology has been chosen to be the new chairman of California’s $3 billion stem cell research program, taking over at a time when the state’s fiscal crisis could jeopardize financing for the effort. The banker, Jonathan Thomas, replaces Robert N. Klein, who has...
News Story
6/23/2011
Posted by Mark Reback
Jonathan Thomas, an investment banker and attorney from Santa Monica, was nominated by Gov. Jerry Brown, Lt. Gov. Gavin Newsom and Treasurer Bill Lockyer to become the new chairman of the oversight committee of the California Institute for Regenerative Medicine. Frank Litvack, a cardiologist and business executive from Los Angeles,...